[1] |
YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan.
Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
|
[2] |
WU Yujie, ZHAO Chengcheng, XI Qing.
Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
|
[3] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[4] |
DENG Zhaoya, LI Yan, LIU Jian, HUANG Yinjiu.
Study on the inhibition of compound salvia miltiorrhiza on the proliferation of ovarian cancer cells and its preliminary mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 526-534.
|
[5] |
ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng.
Model informed precision dosing of warfarin: China expert consensus report (2022 version)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
|
[6] |
LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan.
Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
|
[7] |
ZHANG Ningyuan, ZHENG Xijun, XU Ling, LIU Hongxia, ZHENG Qingshan.
Disease progression model for Alzheimer's disease and its research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 687-694.
|
[8] |
JING Yongshuai, ZHANG Yuwei, WU Lanfang, ZHANG Ruijuan, MA Yunfeng, ZHANG Danshen.
Research progress on extraction methods and pharmacological activities of polysaccharide from traditional Chinese herb compound
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 462-468.
|
[9] |
JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan.
Model informed precision dosing: China expert consensus report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
|
[10] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|
[11] |
XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping.
Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
|
[12] |
SONG Xin, WANG Xue, ZHOU Huanghong, ZHAO Tianyi.
Effect of compound glycyrrhizin on the expression and clinical prognosis of antibacterial peptide LL-37 in patients with pigmentary purpuric skin disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 458-463.
|
[13] |
LI Hong, LIU Yeqian, GONG Shan, LIU Lin, ZENG Yong, CAI Xiao, WANG Yuhong, REN Weiqiong.
Compound Qishao Jiangya tablet reduces blood pressure in mesenteric artery of SHR rats by decreasing the deposition of type Ⅰ and type III collagen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1364-1370.
|
[14] |
ZHANG Huimin, LIU Aiming, ZHU Wenfeng, YU Lingzhi, CHEN Fangliang.
Scientific decision process and regulation requirements based on the current guidelines of data extrapolation from adult to pediatric population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 49-56.
|
[15] |
YIN Fang, WANG Yuzhu, ZHENG Qingshan.
Dose selection of indacaterol for marketing approval: a FDA story in pharmacometrics review
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1031-1039.
|